NeuroStim Medical Launches 'TwinStar System', Pioneering the DBS 2.0 Era with Multi-Circuit Neuromodulation

August 8, 2025, "The 22nd Academic Conference of the Neurosurgery Branch of the Chinese Medical Association"During the period, Sceneray Medical held "DBS 2.0 Era: Multi-Neural Circuit Combined Modulation and Sceneray Gemini System New Product Launch" has attracted widespread attention. At the meeting,ScenerayOfficial LaunchGemini System (SR1384Y Type Extension Lead), heralding the entry of DBS (Deep Brain Stimulation) technology into the 2.0 era and embarking on a new exploration of multi-neural circuit combined modulation.

DBS Technology as a Key Treatment Method in the Field of Neuroscience Has Always Played an Important Role in Improving Patients' Quality of Life. However, Traditional DBS Technology Still Has Certain Limitations in the Treatment of Some Complex Conditions. Sceneray Has Long Been Committed to Brain Science Exploration and Always Regards the Improvement of Efficacy as Its Core Goal. The TwinStar System Launched This Time Is Another Significant Achievement on Its Path of Technological Innovation.

At the press conference, Zhujiang Hospital of Southern Medical UniversityZhang ShizhongProfessor presided over and delivered a speech, stating that in the past, we have continuously strived to optimize the efficacy of DBS; now, we are officially ushering in a new chapter of enhanced efficacy, entering the DBS 2.0 era of multi-neural circuit combined modulation. In this era, we advocate for the freedom to innovate efficacy and explore infinite possibilities, aiming to achieve greater freedom in efficacy and push the boundaries of exploration. As is well known, the efficacy of DBS has always been a focal point of great concern for doctors, especially when facing situations with multiple coexisting symptoms. The key to enhancing efficacy lies in how to transition from single-target treatment to multi-target treatment, and from fixed parameter modes to freely programmable modes. DBS 2.0 is redefining the upper limits of efficacy. Today, let us witness together how the Gemini system empowers clinicians with more choices and exploration space, thereby customizing personalized neural circuit solutions for each patient.

Chairman of ScenerayNing YihuaMr. inThe DBS 2.0 Era: Multi-Neural Circuit Combined ModulationIn China, it was noted that 30 years ago, neuromodulation technology ushered in a new era for Parkinson's disease treatment. However, previous technological advancements primarily focused on single-target and single neural circuit interventions. Given that neurological disorders often involve damage to multiple neural circuits, single-target modulation has many limitations, such as the inability to address freezing of gait, long-term tolerance, and declining efficacy. Now, with the launch of the Gemini system, it marks the beginning of the DBS 2.0 multi-neural circuit combined modulation era. This system can modulate multiple neural circuits simultaneously, offering new treatment approaches for various symptoms. Combined with visualized programming control, it is expected to break through the efficacy ceiling. Sceneray looks forward to collaborating with experts to lead the development of DBS technology.

Shanghai Jiao Tong University Affiliated Sixth People's HospitalWanhai DingProfessor's SharingDBS 2.0 Era: Preliminary Study on STN+NAc Dual-Target Treatment for Parkinson's Disease with Psychiatric DisordersShare and expressAbout 50% of patients with Parkinson's disease also suffer from psychiatric disorders such as anxiety and depression, and there is a contradiction between anti-Parkinson drugs and antipsychotic drugs, which affects treatment outcomes. Using an 8-contact system, a "4+4" mode can be adopted, placing 4 contacts in the STN nucleus to address motor disorders, and the other 4 contacts in the anterior limb of the internal capsule and the ventral striatum to modulate the psychiatric circuit, achieving dual-target combination therapy. Clinical cases show that this solution can significantly reduce psychiatric symptom scores, decrease hallucinations and delusions, and improve both motor and psychiatric issues in a single surgery.

Shanghai Donglei Brain HospitalHu XiaowuThe professor then addressed"STN+GPi Dual-Target Treatment for Movement Disorders"Elaborate. The newly launched extension lead adapter is ingeniously designed and holds significant clinical importance. In terms of target selection, the dual-target treatment of STN and GPi for movement disorders achieves an effect of 1+1>1, with complementary functions. The new device's extension lead is soft, the helical shell is smaller, and the pulse generator is compact and lightweight, making surgical procedures more convenient. Through case presentations, such as patients with Parkinson's disease and dystonia, the "one-to-four" dual-target stimulation allows for self-controlled trials, showing ideal results. It offers convenience to doctors with manageable risks, achieving optimal outcomes in one step.

At the new product launch ceremony,Zhang ShizhongProfessor,Ning YihuaMr.,Ding WanhaiProfessor &Hu XiaowuProfessors took the stage together and pressed the launch button, marking the official release of Sceneray's Gemini System (SR1384Y Lead Extension). This milestone event not only announces the arrival of the DBS 2.0 era but also achieves more flexible neural circuit intervention through innovative lead extension design, paving a new path for revolutionizing the treatment model of neurological disorders and improving patient outcomes.

In the future, Sceneray will continue to deepen its expertise in the field of neuroscience, prioritizing therapeutic efficacy. Collaborating with medical professionals, it will persistently push the boundaries of neuromodulation technology, advancing the treatment of neurological disorders worldwide toward precision and personalization, allowing more patients to benefit from innovative Chinese medical technologies. We look forward to the brilliant performance of Sceneray's Gemini System in clinical applications, illuminating hope for more patients and leading neuroscience into a broader exploration journey.